Tilray(US:TLRY)2026-01-08 22:32Financial Data and Key Metrics Changes - The company reported a record Q2 net revenue of $218 million, with an adjusted EBITDA of $8.4 million and a reported EPS loss of $0.02, reflecting a significant improvement in performance metrics [4][22]. - The net loss for the quarter was $43.5 million, a 49% improvement year-over-year compared to $85.3 million, with cash flow used in operations down to $8.5 million from $40.7 million last year [27][28]. Business Line Data and Key Metrics Changes - Cannabis net revenue increased to $67.5 million, driven by a 36% increase in international cannabis revenue and a 6% increase in Canadian adult use cannabis [22][23]. - Beverage revenue totaled $50.1 million, impacted by headwinds in the craft beer segment, while distribution revenue grew by 26% year-over-year to $85.3 million [11][25]. - Wellness revenue remained flat at $14.6 million, with challenges in the club retail channel being addressed [20][25]. Market Data and Key Metrics Changes - International cannabis revenue reached $20 million, marking a 51% sequential growth and a 36% year-over-year increase [9][22]. - The Canadian adult use medical sales channel net of excise tax grew to $46 million, with recreational cannabis growing 6% in the quarter [12][22]. Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and liquidity to capitalize on growth opportunities in the evolving global cannabis regulatory environment, particularly in the U.S. [5][29]. - Tilray is focused on expanding its pharmacy reach in Germany and tripling its medical cannabis distribution footprint in fiscal 2026 [10][11]. - The company is also pursuing international growth by expanding its beverage business into new markets, including the U.K., Middle East, and Africa [19][20]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory for the second half of fiscal 2026 and beyond, citing a diversified platform and improving fundamentals [21][29]. - The company is prepared for potential regulatory changes in the U.S. regarding cannabis rescheduling, which could enhance its market position [7][87]. Other Important Information - The company ended the quarter with approximately $292 million in cash and marketable securities, with a net cash position exceeding debt by almost $30 million [5][28]. - The company is committed to investing in research and clinical trials to develop approved cannabis drugs for various medical conditions [85][86]. Q&A Session Summary Question: What can the industry do to improve the regulatory outcome regarding the intoxicating hemp ban? - Management is working with legislators to extend the deadline or modify regulations to allow for a regulated amount of milligrams to be sold nationally [32][34]. Question: Can you quantify how much supply was held back from the Canadian wholesale market? - Approximately $5 million worth of supply was held back, which will be redeployed into higher-margin international markets [38][39]. Question: How much of the Canadian adult use cannabis growth was volume versus price mix? - The growth was primarily driven by demand and new distribution, with a slight market share gain [44][46]. Question: What are the expectations for growth within the Canadian market? - Management expects mid- to high single-digit growth in the Canadian market, focusing on premium products and new product launches [58][60]. Question: Can you provide more color on the CC Pharma business and its distribution reach? - The company has modernized CC Pharma and is focused on expanding its pharmacy reach, with plans to sell more medical cannabis through its sales organization [66][68]. Question: What is the long-term outlook for the beverage business? - Management remains confident in the beverage business, emphasizing the importance of integration and the potential for future opportunities in cannabis-infused drinks [76][77].